In late March, the Federal Circuit issued an order staying the PTAB
proceedings concerning numerous related IPRs of patents issued to
Allergan, Inc. ("Allergan"), but assigned to the Saint
Regis Mohawk Tribe ("the Tribe"). These IPRs were headed
toward a final hearing on the merits previously scheduled for April
3rd. In those IPRs, the PTAB denied the Tribe's motions to
terminate the proceedings based upon the Tribe's sovereign
immunity. Mylan Pharma Inc. v. Saint
Regis Mohawk Tribe, Case IPR2016-01127, Paper 130
(February 23, 2018). This post explains the PTAB's decision
that the court will now review on appeal. On December 8, 2016, the
Board had instituted IPR proceedings for the Allergan
Restasis® patents in response to petitions filed by
Mylan Pharmaceuticals, Inc. ("Mylan") and various
later-joined Petitioners Less than a week before final hearing,
counsel for the Tribe informed the Board that the Tribe had
acquired the challenged patents from Allergan. The Tribe